Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife’s Chinese provinces

This article was originally published in The Tan Sheet

Executive Summary

China's Ministry of Commerce grants the Los Angeles-based nutritional products direct-seller five additional licenses to conduct direct-selling business in the Beijing, Guangdong, Shandong, Zhejiang and Guizhou provinces. The licenses are effective immediately except for the Beijing province, which will activate after the firm opens service outlets, Herbalife says July 20. Herbalife received its first direct-selling license for China in March 2007, covering Suzhou and Nanjing in the Jiangsu province. The licenses allow distributors to conduct business outside retail locations in the specific province and cities ("The Tan Sheet" April 2, 2007, In Brief)...

You may also be interested in...



Social Clubs Help Deepen Herbalife’s Reach In Existing Markets

Herbalife is focusing more on extending the "daily consumptive model" for direct-selling nutritional products, which has driven the firm's double-digit sales growth for 18 consecutive quarters, deeper into its existing markets than on reaching additional markets

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.

Day One Springs Into Commercial Action With Ojemda Approval

The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel